Gilead HIV Success Seen As Bulwark Against Patent Loss, Competition
May 30, 2017 at 20:29 PM EDT
Gilead announced Tuesday that its latest HIV treatment candidate met its primary goal in four late-stage studies, showing "non-inferiority" against existing regimens, including a competitor from GlaxoSmithKline.
